Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and neck. Although patients with locoregionally advanced SCCHN are generally prescribed chemotherapy-based regimens, targeted therapies are frequently prescribed to patients with recurrent or metastatic disease. The usual treatment algorithm starts with a PD-1 inhibitor (pembrolizumab [Keytruda]) for recurrent or metastatic disease, followed by an EGFR-targeting agent (cetuximab [Erbitux]) after progression. The expected approval of zanzalintinib (in combination with pembrolizumab) as a first-line treatment, along with the approval of petosemtamab (in combination with pembrolizumab), will significantly impact treatment in the recurrent and metastatic settings during the 2023-2033 forecast period. Buparlisib (in combination with paclitaxel), ficlatuzumab (in combination with cetuximab), and petosemtamab in later-line treatment will also contribute to this transformation. Finally, the approval of toripalimab is setting a new treatment paradigm for SCCHN. We anticipate strong adoption of toripalimab, alongside the immune checkpoint inhibitor penpulimab, whose approval we expect soon.

Questions answered

• What is the anticipated evolution in the size of the drug-treatable SCCHN populations from 2023 to 2033, and how will it impact the landscape of available treatment options?
• What are the key current therapies for locoregionally advanced and recurrent or metastatic SCCHN, and what is their positioning?
• How will drugs in late-phase development for SCCHN gain market and patient share?
• What are the driving forces and limitations influencing the SCCHN therapy market, and how do experts foresee these factors evolving over the 10-year forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.